New combo therapy offers hope for hard-to-treat stomach cancer
NCT ID NCT06085755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced HER2-low stomach cancer that has not responded to earlier treatments. It tests a combination of two targeted drugs, trastuzumab deruxtecan (T-DXd) and afatinib, to see if they work better together. The goal is to shrink tumors and improve survival, while carefully monitoring safety. About 61 adults will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC ADENOCARCINOMA OF GASTRIC OR GASTROESOPHAGEAL JUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple test could spot who will develop stomach cancer
- New rehab model aims to boost recovery for stomach and esophageal cancer patients
- New chemo cocktail aims to make inoperable stomach cancer removable
- Can adding radiation before surgery help stomach cancer patients live longer?
- Triple-Drug cocktail targets stomach cancer that has spread to the abdomen
- New targeted drug shows promise for Hard-to-Treat stomach cancers